Quaternary ammonium compounds having an isopropyl methylphenol moiety as antiviral, antibacterial and antifungal agents

By developing compounds with specific structures and combining aromatic thymeol and carvacrol groups, the problem of the inability of the prior art to completely eradicate the resistance of herpes virus and antibiotics has been solved, and the herpes virus, human papillomavirus, and bacteria have been achieved. and effective treatment of fungi.

CN114026061BActive Publication Date: 2024-12-03RHEA GENETICS PTE LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202080039366.3
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2019-04-16
Filing Date
2020-04-16
Publication Date
2024-12-03
Estimated Expiration
2040-04-16

AI Technical Summary

Technical Problem

Existing antiviral drugs cannot completely eradicate the herpes virus, and antibiotic resistance to bacterial and fungal infections is increasing, resulting in a lack of effective treatment options.

Method used

A compound with alkylene chains with 8 to 20 carbon atoms and specific anionic or quaternary amine structures combined with aromatic thyme and carvacrol groups exhibits antibacterial, antifungal and antiviral activities, Its properties are further enhanced by complexing with bromine to form a pharmaceutical composition for the treatment of related infections.

Benefits of technology

The compound exhibits significant antibacterial, antifungal and antiviral activities, and is able to effectively treat herpesvirus, human papillomavirus, bacterial and fungal infections, providing new therapeutic options, especially effective against antibiotics and antifungal-resistant strains .

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN114026061B_ABST
    Figure CN114026061B_ABST
Patent Text Reader

Abstract

Disclosed are compounds having the following formula (I): Formula (I), wherein R is an alkylene chain having 8 to 20 carbon atoms, and A is one or more anions with a total charge of -2, or R is a quaternary amine having the following formula (Ia): Formula (Ia), wherein R a and R b Each is an alkylene chain having 8 to 20 carbon atoms, and A is one or more anions with a total charge of -3; R 1 , R 2 , R 3 , R 4 , R 5 and R 6 Each independently selected from C 1‑10 alkyl and H; E has the following formula (Ib), wherein the ester oxygen is bonded to the aromatic ring of each E at the same position, which is the 2-position or the 3-position; and wherein R E It is H or halogen. #imgabs0#
Need to check novelty before this filing date? Find Prior Art

Description

[0001] The present invention relates to compounds that can be used to treat viral, bacterial and fungal infections.

[0002] background

[0003] The Herpesviridae is a large family of DNA viruses that can cause a variety of diseases in humans and animals. The most common Herpesviridae that cause disease in humans are Varicella Zostervirus, Epstein-Barr virus, Cytomegalovirus, Herpes Simplex virus 1, and Herpes Simplex virus 2.

[0004] Varicella-zoster virus is a common virus that causes chickenpox in children and shingles in adults.

[0005] Epstein-Barr virus is the virus that commonly causes infectious mononucleosis (glandular fever) and has also been associated with cancers such as Hodgkin lymphoma, Burkitt lymphoma, and gastric cancer.

[0006] Cytomegalovirus is another member of the Herpesviridae family of viruses. Human cytomegalovirus (HCMV or CMV or human herpesvirus-5 (HHV-5)) is a virus associated with the salivary glands that is usually unnoticed by healthy individuals but can be life-threatening to immunocompromised individuals such as patients with HIV, organ transplant recipients, and newborns.

[0007] Herpes simplex virus 1 and herpes simplex virus 2 are both viruses that can cause the viral disease herpes simplex. Both viruses can cause oral and genital infections, although HSV-1 is more commonly associated with oral infections (e.g., oral herpes) and HSV-2 is more commonly associated with genital infections (e.g., genital herpes). Infections caused by herpes simplex viruses affect approximately 60% to 95% of adults worldwide (Chayavichitsilp P, Buckwalter JV, Krakowski AC, Friedlander SF (April 2009). "Herpes simplex". Pediatr Rev. 30 (4)).

[0008] Oral herpes is usually associated with the face and / or mouth and may result in small blisters that form herpes labialis (herpes labialis). Oral herpes may also include other symptoms such as sore throat, fever, muscle pain, swollen lymph nodes, headache and malaise, especially during the first episode after a person is infected.

[0009] Genital herpes is usually associated with the genitals and may cause small lesions in the genital area, inner thighs, buttocks and / or anus. Other typical symptoms associated with the virus include pain, itching, burning, discharge, fever, headache, muscle pain, swollen lymph nodes and discomfort.

[0010] Oral herpes can be treated with antiviral medications, which can reduce the duration of symptoms but cannot completely kill the causative virus. After the symptoms of an oral herpes infection subside, the herpes virus (such as HSV-1 or HSV-2) often remains dormant in branches of the facial nerve, and the virus can periodically reactivate to produce cold sores in the same area of ​​the mouth or face as the original infection site. In some people, the virus remains asymptomatic, although it can be transmitted even when symptoms are not present.

[0011] Genital herpes can also be treated with antiviral medications, which may reduce the duration of symptoms. However, for oral herpes, there are no approved medications that can completely eradicate the causing virus in the body.

[0012] Human papillomavirus (HPV) causes human papillomavirus infection, which usually does not cause symptoms and resolves spontaneously. However, in some cases, the infection persists and causes warts or precancerous lesions. Precancerous lesions may increase the risk of many types of cancer, including cervical cancer, vaginal cancer, penile cancer, anal cancer, oral cancer, and throat cancer (Ljubojevic, Suzana; Skerlev, Mihael (2014). "HPV-associated diseases". Clinics in Dermatology. 32 (2): 227–234.). HPV is the most common sexually transmitted infection worldwide, and most people are infected at some point in their lives (Milner, Danny A. (2015). Diagnostic Pathology: Infectious Diseases. Elsevier Health Sciences. p. 40).

[0013] Bacterial and fungal infections are common throughout the world. Various drugs have been developed to treat such infections, and these drugs can target specific or broad types of bacterial and fungal species and strains. Antibiotic resistance and more recently antifungal resistance are becoming more common and are an increasing problem worldwide. With this in mind, there is a global need for new drugs that can treat bacterial and fungal infections.

[0014] Given the prevalence of herpes viruses (particularly herpes simplex virus) and human papillomavirus and the range of diseases associated with these viruses, there is a need for treatments that target these viruses and can treat diseases associated with these viruses.

[0015] Compounds showing antibacterial, antifungal and antifungal effects have been disclosed, examples of such compounds are disclosed in WO2018132066. There continues to be a need for compounds having antibacterial, antiviral and antifungal effects.

[0016] In a first aspect of the present invention, there is provided a compound having the formula:

[0017]

[0018] wherein R is an alkylene chain having 8 to 20 carbon atoms, and A is one or more anions having a total charge of -2;

[0019] Alternatively, R is a quaternary amine having the formula:

[0020]

[0021] Where R a and R b Each is an alkylene chain having 8 to 20 carbon atoms, A is one or more anions, and the total charge is -3.

[0022] R1, R2, R3, R4, R5 and R6 are each independently selected from C 1-10 Alkyl and H;

[0023] E has the following formula wherein the ester oxygen is bonded to the aromatic ring of each E at the same position, which is the 2-position or the 3-position; and wherein R E is H or halogen.

[0024] R can be, for example, a straight or branched saturated or unsaturated alkylene chain having 8 to 18 carbon atoms, such as 8 to 16 carbon atoms, such as 8 to 14 carbon atoms, such as 9 to 15 carbon atoms, such as 10 carbon atoms. Preferably, R is a saturated straight alkylene chain having 8 to 16 carbons, such as 10 carbon atoms. In this context, alkylene refers to a diradical based on an alkane, and therefore has two points of attachment to the rest of the molecule.

[0025] R may be, for example, a quaternary amine according to formula (Ia) wherein R a and R b Each is a straight or branched saturated or unsaturated alkylene chain having 8 to 18 carbon atoms, such as 8 to 16 carbon atoms, such as 8 to 14 carbon atoms, such as 9 to 15 carbon atoms, such as 10 carbon atoms. a and R b Each may be a straight or branched saturated alkylene chain having a different number of carbon atoms or the same number of carbon atoms.

[0026] Preferably, R a and R b Each is a straight saturated alkylene chain having 8 to 16 carbon atoms, for example 10 carbon atoms.

[0027] A saturated straight alkylene chain can be represented by the formula: wherein n is the number of repeating units, i.e. the number of carbon atoms in the linear alkylene chain. Thus, in the case where R is an alkylene chain having 8 to 20 carbon atoms, preferably R is wherein n is 8 to 16, for example 10. In the case where R is a quaternary amine having formula (Ia) as described above, preferably R a and R b yes wherein n is 8 to 16, for example, 10.

[0028] For example, in the case where R is an alkylene chain having 10 carbon atoms, R may be represented by the formula express.

[0029] A may, for example, include a halide ion such as chloride (Cl - ) ion, bromine (Br - ) ions, iodide ions (I - ) and / or fluoride ions (F - A may include, for example, ions of other organic acids and non-organic acids, such as sulfate (SO4 2- ), carbonate (CO3 2- ), bicarbonate (HCO3 - ), hydrogen sulfate (HSO4 - ), acetate ion (CH3COO - ) and / or formate ions (HCOO - ). In the case where R is an alkylene chain having 8 to 20 carbon atoms, preferably, A comprises two halide ions, such as two chloride ions, so that the total charge is -2. In the case where R is a quaternary amine having formula (Ia) as described above, preferably, A comprises two chloride ions and one bromide ion, so that the total charge is -3.

[0030] R1, R2, R3, R4, R5 and R6 can be independently selected from C 1-4 Alkyl and H, for example, R1, R2, R3, R4, R5 and R6 may each be methyl. E It can be chlorine, bromine, iodine or fluorine. In the case where the ester oxygen is bonded to the aromatic ring of E at the 2 position relative to the methyl group, R E It may be bonded to the aromatic ring at the 3-position, 5-position or 6-position relative to the methyl group. In the case where the ester oxygen is bonded to the aromatic group of E at the 3-position relative to the methyl group, R E The aromatic ring may be bonded at the 2-position, 5-position or 6-position relative to the methyl group.

[0031] Preferably, the compound of formula (I) above has the following formula:

[0032]

[0033] wherein R, R1, R2, R3, R4 and A are as defined above for formula (I).

[0034] Preferably, the compound of formula (I) has the following formula:

[0035]

[0036] In Formula IV and V, it is understood that R is a linear saturated alkylene chain having 10 carbon atoms; A is two chloride ions. In Formula VI and VII, it is understood that R is a quaternary amine, wherein R a and R b Each is a saturated straight alkylene chain having 10 carbon atoms, and A is two chloride ions and one bromide ion. It is understood that in Formulas IV and V, R1, R2, R3 and R4 are each methyl. It is understood that in Formulas VI and VII, R1, R2, R3, R4, R5 and R6 are each methyl.

[0037] In another embodiment of the present invention, there is provided a compound having the formula:

[0038] wherein R is an alkylene chain having 8 to 20 carbon atoms, and A is one or more anions having a total charge of -2;

[0039] Alternatively, R is a quaternary amine having the formula:

[0040]

[0041] Where R a and R bEach is an alkylene chain having 8 to 20 carbon atoms, A is one or more anions with a total charge of -3;

[0042] R1, R2, R3, R4, R5 and R6 are each independently selected from C 1-10 Alkyl and H;

[0043] E has the following formula The ester oxygen is bonded to the aromatic ring of each E at the same position, which is the 2-position or the 3-position; wherein R E is H or halogen, and wherein X is 2, 3, 4 or 6.

[0044] R can be, for example, a straight or branched saturated or unsaturated alkylene chain having 8 to 18 carbon atoms, such as 8 to 16 carbon atoms, such as 8 to 14 carbon atoms, such as 9 to 15 carbon atoms, such as 10 carbon atoms. Preferably, R is a straight saturated alkylene chain having 8 to 16 carbon atoms, such as 10 carbon atoms.

[0045] R may be, for example, a quaternary amine according to formula (Ia) wherein R a and R b Each is a straight or branched saturated or unsaturated alkylene chain having 8 to 18 carbon atoms, such as 8 to 16 carbon atoms, such as 8 to 14 carbon atoms, such as 9 to 15 carbon atoms, such as 10 carbon atoms. a and R b Each may be a straight or branched saturated alkylene chain having a different number of carbon atoms or the same number of carbon atoms.

[0046] Preferably, R a and R b Each is a straight saturated alkylene chain having 8 to 16 carbon atoms, for example 10 carbon atoms.

[0047] A saturated straight alkylene chain can be represented by the formula:

[0048] wherein n is the number of repeating units, i.e. the number of carbon atoms in the linear alkylene chain. Thus, in the case where R is an alkylene chain having 8 to 20 carbon atoms, preferably R is wherein n is 8 to 16, for example 10. In the case where R is a quaternary amine having formula (Ia) as described above, preferably R a and R b yes wherein n is 8 to 16, for example, 10.

[0049] In the case where, for example, R is an alkylene group having 10 carbon atoms, R may be represented by the formula express.

[0050] A may, for example, comprise a halide ion such as chloride (Cl - ) ion, bromine (Br - ) ions, iodide ions (I - ) and / or fluoride ions (F - A may, for example, contain ions of other organic and non-organic acids, such as sulfate (SO4 2- ), carbonate (CO3 2- ), bicarbonate (HCO3 - ), hydrogen sulfate (HSO4 - ), acetate (CH3COO - ) and / or formate ions (HCOO - ). In the case where R is an alkylene chain having 8 to 20 carbon atoms, preferably, A comprises two halide ions, such as two chloride ions, so that the total charge is -2. In the case where R is a quaternary amine having formula (Ia) as described above, preferably, A comprises two chloride ions and one bromide ion, so that the total charge is -3.

[0051] R1, R2, R3, R4, R5 and R6 can be independently selected from C 1-4 Alkyl and H, for example, R1, R2, R3, R4, R5 and R6 may each be methyl.

[0052] R E It can be chlorine, bromine, iodine or fluorine. In the case where the ester oxygen is bonded to the aromatic ring of E at the 2 position relative to the methyl group, R E It may be bonded to the aromatic ring at the 3-position, 5-position or 6-position relative to the methyl group. In the case where the ester oxygen is bonded to the aromatic group of E at the 3-position relative to the methyl group, R E The aromatic ring may be bonded at the 2-position, 5-position or 6-position relative to the methyl group.

[0053] Preferably, the compound of formula (VIII) above has the following formula:

[0054]

[0055] wherein R, R1, R2, R3, R4, X and A are as defined above for formula (IX).

[0056] Preferably, the compound of formula (VIII) has the following formula:

[0057]

[0058] Where X is 3 or 6.

[0059] In formulae (XI) and (XII), it is understood that R is a linear saturated alkylene chain having 10 carbon atoms; and A is two chloride ions.

[0060] In formula (XIII) and (XIV), it is understood that R is a quaternary amine, wherein R a and R b Each is a saturated straight alkylene chain having 10 carbon atoms, and A is two chloride ions and one bromide ion. It is understood that in formulas (XI) and (XII), R1, R2, R3 and R4 are each methyl. It is understood that in formulas (XIII) and (XIV), R1, R2, R3, R4, R5 and R6 are each methyl.

[0061] Applicants have discovered that the above compounds represented by Formulae I to XIV exhibit surprising antibacterial, antifungal and antiviral activity. Without being bound by any particular theory, it is hypothesized that this antibacterial and antifungal activity may stem from the combination of aromatic thymol and carvacrol groups, quaternary amino groups and long chain alkyl groups. Additionally, complexing the compounds according to Formulae I-IV with bromine may further increase their antibacterial and antifungal properties.

[0062] Applicants have discovered that compounds represented by Formulae I to XIV exhibit enhanced antibacterial, antifungal and antiviral activity over similar compounds in which the ester oxygen is bonded to the aromatic ring of each group E at a different position.

[0063] In another aspect of the present invention, there is provided a pharmaceutical composition (eg, a pharmaceutical composition for human use and / or a pharmaceutical composition for veterinary use) comprising a compound according to formula (I) to (XIV) above.

[0064] The pharmaceutical composition can be in a form suitable for one or more of oral, rectal, parenteral, transdermal, intravenous, intraarterial, intraosseous infusion, intracerebral, intracerebroventricular, intrathecal, intramuscular, subcutaneous, intravaginal, intraperitoneal, epidural, intracerebral, intraosseous infusion, intravitreal, transmucosal, buccal, or nasal administration.

[0065] The pharmaceutical composition may comprise a compound according to formula (I) to (XIV), a pharmaceutically acceptable carrier such as an aqueous solution, a non-toxic excipient (including salts and preservatives), a buffer, and the like.

[0066] Examples of suitable aqueous and non-aqueous pharmaceutical carriers, diluents, solvents or vehicles include water, ethanol, polyols (such as glycerol, propylene glycol, polyethylene glycol, etc.), carboxymethyl cellulose and suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters (such as ethyl oleate).

[0067] Examples of pharmaceutically acceptable excipients include antiadherents, binders, coatings, colorants, disintegrants, flavoring agents, glidants, lubricants, preservatives, adsorbents, and sweeteners.

[0068] The pharmaceutical composition of the present invention may also contain additives, such as but not limited to preservatives, wetting agents, emulsifiers, surfactants and dispersants. Antibacterial and antifungal agents may be included to prevent the growth of microorganisms, including, for example, meta-cresol, benzyl alcohol, parabens, chlorobutanol, phenol, sorbic acid, etc. If a preservative is included, benzyl alcohol, phenol and / or meta-cresol are preferred; however, the preservative is by no means limited to these examples. In addition, isotonic agents such as sugars, sodium chloride, etc. may need to be included.

[0069] Pharmaceutical compositions suitable for oral administration may be in the form of, for example, tablets, pills, dragees, powders, capsules, liquids, gels, syrups, slurries, suspensions, cachets, etc. The composition may contain a pharmaceutically acceptable carrier such as liposomes, lactose, trehalose, sucrose, mannitol, xylitol, crystalline cellulose, chitosan, calcium carbonate, talc, titanium oxide, silicon dioxide, etc.

[0070] Pharmaceutical compositions can be obtained, for example, by combining the compounds of the invention with solid excipients, pulverizing the mixture (if necessary) and inserting into capsules (e.g., sealed soft capsules consisting of gelatin capsules, gelatin and a coating (e.g., glycerol or sorbitol), or capsule compositions suitable for vegetarians. In soft capsules, the composition can be dissolved or suspended in a suitable liquid (e.g., fatty oils, liquid paraffin, or liquid polyethylene glycol) with or without a stabilizer.

[0071] In another aspect of the present invention, there is provided a compound or pharmaceutical composition as described above for use as a medicament.

[0072] In another aspect of the present invention, there is provided a compound or pharmaceutical composition as described above for use in treating herpes virus, human papillomavirus, bacterial infection and / or fungal infection.

[0073] The herpes virus can be one or more of herpes simplex virus, herpes simplex virus 1 (HSV-1), herpes simplex virus 2 (HSV-2), varicella zoster virus (VZV), Epstein-Barr virus, cytomegalovirus, human cytomegalovirus, roseolavirus, Kaposi's Sarcoma-associatedherpesvirus, animal herpesvirus (such as Pseudorabies virus and Bovine herpesvirus 1).

[0074] Preferably, the herpes virus is a herpes simplex virus (eg, herpes simplex virus 1 or herpes simplex virus 2) or a cytomegalovirus.

[0075] Bacterial infections can include infections caused by Gram-positive and / or Gram-negative bacteria.

[0076] Bacterial infections may be caused, for example, by Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa, and / or Salmonella enterica bacteria.

[0077] Fungal infections can be superficial mycoses, dermatophytes, subcutaneous mycoses, and / or systemic mycoses.

[0078] Fungal infections can be caused, for example, by Candida albicans.

[0079] In another aspect of the present invention, there is provided use of the compound or pharmaceutical composition as described above in the preparation of a medicament for treating herpes virus, human papillomavirus, bacterial infection and / or fungal infection.

[0080] The herpes virus can be one or more of herpes simplex virus, herpes simplex virus 1 (HSV-1), herpes simplex virus 2 (HSV-2), varicella-zoster virus (VZV), Epstein-Barr virus, cytomegalovirus, human cytomegalovirus, roseola virus, Kaposi's sarcoma-associated herpes virus, animal herpes virus (such as pseudorabies virus) and bovine herpes virus 1.

[0081] Preferably, the herpes virus is a herpes simplex virus (eg, herpes simplex virus 1 or herpes simplex virus 2) or a cytomegalovirus.

[0082] Bacterial infections can include infections caused by Gram-positive and / or Gram-negative bacteria.

[0083] Bacterial infections may be caused by, for example, Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa and / or Salmonella enterica bacteria.

[0084] Fungal infections can be superficial mycoses, dermatophytes, subcutaneous mycoses, and / or systemic mycoses.

[0085] Fungal infections may be caused, for example, by Candida albicans.

[0086] In another aspect of the present invention, a method for treating herpes virus, human papillomavirus, bacterial infection and / or fungal infection is provided, comprising the step of administering to a subject the compound or pharmaceutical composition as described above.

[0087] The herpes virus can be one or more of herpes simplex virus, herpes simplex virus 1 (HSV-1), herpes simplex virus 2 (HSV-2), varicella-zoster virus (VZV), Epstein-Barr virus, cytomegalovirus, human cytomegalovirus, roseola virus, Kaposi's sarcoma-associated herpes virus, animal herpes virus (such as pseudorabies virus) and bovine herpes virus 1.

[0088] Preferably, the herpes virus is a herpes simplex virus (eg, herpes simplex virus 1 or herpes simplex virus 2) or a cytomegalovirus.

[0089] Bacterial infections can include infections caused by Gram-positive and / or Gram-negative bacteria.

[0090] Bacterial infections may be caused by, for example, Staphylococcus aureus, Escherichia coli, Pseudomonas aeruginosa and / or Salmonella enterica bacteria.

[0091] Fungal infections can be superficial mycoses, dermatophytes, subcutaneous mycoses, and / or systemic mycoses.

[0092] Fungal infections may be caused, for example, by Candida albicans.

[0093] In yet another aspect of the present invention, there is provided a method for producing a compound according to formula (I), comprising the following steps:

[0094] i) making a compound having formula (XV)

[0095] wherein the alcohol group is bonded to the benzene ring at the 2-position or 3-position, and wherein R E is H or halogen,

[0096] Reaction with R7CH2COCl to form a compound having formula (XVI):

[0097]

[0098] Where R7 is chlorine or bromine, E is The ester oxygen is bonded to the aromatic ring of E at the 2- or 3-position, R E is H or a halogen; and

[0099] ii) one molar equivalent of a compound having formula (XVII)

[0100]

[0101] and reacted with 2 moles of a compound having formula (XVI) to form a compound having the following formula:

[0102]

[0103] wherein R is an alkylene chain having 8 to 20 carbon atoms, and A is one or more anions having a total charge of -2;

[0104] Alternatively, R is a quaternary amine having the formula:

[0105]

[0106] Where R a and R b Each is an alkylene chain having 8 to 20 carbon atoms, A is one or more anions with a total charge of -3;

[0107] E has the following formula The ester oxygen is bonded to the aromatic ring of each E at the same position, which is the 2-position or the 3-position; R E is H or halogen;

[0108] R1, R2, R3, R4, R5 and R6 are each independently selected from C 1-10 Alkyl and H.

[0109] The reaction in step ii can be carried out in acetonitrile as a solvent.

[0110] In the case where R is an alkylene chain having 8 to 20 carbon atoms, the method may comprise the additional step of: making a The compound of the formula The compound is reacted to form a compound having the formula A ditertiary amine, wherein R3 and R4 are the same as R1 and R2, and R1 and R2 are each independently selected from C 1-10 Alkyl and H;

[0111] wherein R8 is a halogen, such as bromine or chlorine; and R is an alkylene chain having 8 to 20 carbon atoms.

[0112] In the case where R is a quaternary amine having the formula:

[0113]

[0114] Where R a and R b Each is an alkylene chain having 8 to 20 carbon atoms, R5 and R6 are each independently selected from C 1-10 alkyl and H, the method may include the additional step of: making 2 molar equivalents of a The compound with 3 molar equivalents of the formula The compound is reacted to form a compound having the formula A quaternary amine, wherein R a is an alkylene chain having 8 to 20 carbon atoms, R8 is a halogen such as bromine or chlorine, Ra and R b are the same and each is an alkylene chain having 8 to 20 carbon atoms, R1, R2, R3, R4, R5 and R6 are the same and are selected from C 1-10 Alkyl and H.

[0115] The reactions in step i can all be carried out at a temperature of -10°C.

[0116] The method may further include one or more separation and / or extraction steps, for example, the separation step may include column chromatography, low pressure liquid chromatography, high performance liquid chromatography, etc. The purification step may include standard purification methods known in the art, such as filtration, evaporation, liquid-liquid extraction, crystallization, adsorption, recrystallization, chromatography, distillation, etc.

[0117] In another aspect of the present invention, there is provided a method for producing a compound according to formula (VIII), the method comprising subjecting a compound having formula (I) to

[0118]

[0119] Reaction with bromine to form a compound having formula (VIII)

[0120]

[0121] wherein R is an alkylene chain having 8 to 20 carbon atoms, and A is one or more anions having a total charge of -2;

[0122] Alternatively, R is a quaternary amine having the formula:

[0123] Where R a and R b Each is an alkylene chain having 8 to 20 carbon atoms, and A is one or more anions with a total charge of -3.

[0124] R1, R2, R3, R4, R5 and R6 are each independently selected from C 1-10 Alkyl and H;

[0125] E has the following formula The ester oxygen is bonded to the aromatic ring of each E at the same position, which is the 2-position or the 3-position; R E is H or halogen;

[0126] and wherein X is 2, 4, 3 or 6.

[0127] The present invention will now be described with reference to the following examples.

[0128] Example 1

[0129] Synthesis of compounds of formula (IV).

[0130]

[0131] In the first step, 1,10-dibromodecane is reacted with 2 molar equivalents of dimethylamine to form 1,10-bis(dimethylamino)decane. The reaction is carried out at 4-5°C in a suitable solvent such as benzene, diethyl ether or dimethylamine, followed by an acid extraction step, followed by a base treatment and extraction with diethyl ether. The extracted fraction is dried over magnesium sulfate and then purified by vacuum distillation.

[0132] In the second step, carvacrol (2-methyl-5-(1-methylethyl)-phenol) is reacted with chloroacetyl chloride. The reaction is carried out at -10°C for 1 hour and then stirred at room temperature for 12 hours. The reaction mixture is then washed with acid, followed by treatment with sodium bicarbonate and then with water. The organic layer is dried over sodium sulfate, filtered and the solvent is removed under vacuum.

[0133] In the third step, 2 molar equivalents of the compound formed in the second step are reacted with 1 molar equivalent of 1,10-bis(dimethylamino)decane to form a compound of formula (IV). The third step reaction is carried out using a suitable solvent such as acetonitrile, and the reaction mixture is stirred for 24 hours.

[0134] It should be understood that further purification and isolation steps may also be included in the process, for example between each of the above steps and after the process is completed, to purify the final compound having formula (IV).

[0135] The separation step may include a step of performing column chromatography, low pressure liquid chromatography, high performance liquid chromatography, etc. The purification step may include standard purification methods known in the art, such as filtration, evaporation, liquid-liquid extraction, crystallization, adsorption, recrystallization, chromatography, distillation, etc.

[0136] The compound of formula (IV) has the following systematic name, molecular formula and molecular weight:

[0137] Systematic name: N1,N10-bis(2-(5-isopropyl-2-methylphenoxy)-2-oxoethyl)-N1,N1,N10,N10-tetramethyldecane-1,10-diammonium dichloride

[0138] Molecular formula: C 38 H 62 N2O4 +2 2Cl -

[0139] Molecular weight: 681.81

[0140]

[0141] Solution 1

[0142] Example 2

[0143] Synthesis of compound of formula (V)

[0144]

[0145] In the first step, 1,10-dibromodecane is reacted with 2 molar equivalents of dimethylamine to form 1,10-bis(dimethylamino)decane. The reaction is carried out in benzene at 4-5°C in a suitable solvent such as benzene, diethyl ether or dimethylamine, followed by an acid extraction step, followed by a base treatment and extraction with diethyl ether. The extracted fraction is dried over magnesium sulfate and then purified by vacuum distillation.

[0146] In the second step, thymol (2-isopropyl-5-methylphenol) is reacted with chloroacetyl chloride. The reaction is carried out at -10°C for 1 hour and then stirred at room temperature for 12 hours. The reaction mixture is then washed with acid, followed by sodium bicarbonate and then water. The organic layer is dried over sodium sulfate, filtered and the solvent removed under vacuum.

[0147] In the third step, 2 molar equivalents of the compound formed in the second step are reacted with 1 molar equivalent of 1,10-bis(dimethylamino)decane to form a compound of formula (V). The third step reaction is carried out using a suitable solvent such as acetonitrile, and the reaction mixture is stirred for 24 hours.

[0148] It should be understood that further purification and isolation steps may also be included in the process, for example between each of the above steps and after the process is completed, to purify the final compound having formula (V).

[0149] The separation step may include a step of performing column chromatography, low pressure liquid chromatography, high performance liquid chromatography, etc. The purification step may include standard purification methods known in the art, such as filtration, evaporation, liquid-liquid extraction, crystallization, adsorption, recrystallization, chromatography, distillation, etc.

[0150] Systematic name: N1,N10-bis(2-(2-isopropyl-5-methylphenoxy)-2-oxoethyl)-N1,N1,N10,N10-tetramethyldecane-1,10-diammonium dichloride

[0151] Molecular formula: C 38 H 62 N2O4 +2 2Cl-

[0152] Molecular weight: 681.81

[0153]

[0154] Solution 2

[0155] Example 3

[0156] Synthesis of compound of formula (VI)

[0157]

[0158] In the first step, 2 molar equivalents of 1,10-dibromodecane are reacted with 3 molar equivalents of dimethylamine. The reaction is carried out at 4-5°C in a suitable solvent such as benzene or diethyl ether, followed by an acid extraction step, followed by a base treatment and extraction with diethyl ether. The extracted fraction is dried over magnesium sulfate and then purified by vacuum distillation.

[0159] In the second step, carvacrol (2-methyl-5-(1-methylethyl)-phenol) is reacted with chloroacetyl chloride. The reaction is carried out at -10°C for 1 hour and then stirred at room temperature for 12 hours. The reaction mixture is then washed with acid, followed by treatment with sodium bicarbonate and then with water. The organic layer is dried over sodium sulfate, filtered and the solvent is removed under vacuum.

[0160] In the third step, 1 molar equivalent of the compound formed in step 1 is reacted with 2 molar equivalents of the compound formed in step 2 to form a compound having formula (VI). The third step reaction is carried out using a suitable solvent such as acetonitrile, and the reaction mixture is stirred for 24 hours.

[0161] It should be understood that further purification and isolation steps may also be included in the process, for example between each of the above steps and after the process is completed, to purify the final compound having formula (VI).

[0162] The separation step may include a step of performing column chromatography, low pressure liquid chromatography, high performance liquid chromatography, etc. The purification step may include standard purification methods known in the art, such as filtration, evaporation, liquid-liquid extraction, crystallization, adsorption, recrystallization, chromatography, distillation, etc.

[0163] Systematic name: N1-(2-(5-isopropyl-2-methylphenoxy)-2-oxoethyl)-N10-(10-((2-(5-isopropyl-2-methylphenoxy)-2-oxoethyl)dimethylammonium)decyl)-N1,N1,N10,N10-tetramethyldecane-1,10-diammonium bromide dichloride

[0164] Molecular formula: C 50 H 88 N3O4 +3 Br - 2Cl -

[0165] Molecular weight: 946.06

[0166]

[0167] Solution 3

[0168] Example 4

[0169] Synthesis of compound of formula (VII)

[0170]

[0171] In the first step, 2 molar equivalents of 1,10-dibromodecane are reacted with 3 molar equivalents of dimethylamine. The reaction is carried out at 4-5°C in a suitable solvent such as benzene or diethyl ether, followed by an acid extraction step, followed by a base treatment and extraction with diethyl ether. The extracted fraction is dried over magnesium sulfate and then purified by vacuum distillation.

[0172] In the second step, thymol (2-isopropyl-5-methylphenol) is reacted with chloroacetyl chloride. The reaction is carried out at -10°C for 1 hour and then stirred at room temperature for 12 hours. The reaction mixture is then washed with acid, followed by sodium bicarbonate and then water. The organic layer is dried over sodium sulfate, filtered and the solvent removed under vacuum.

[0173] In the third step, 1 molar equivalent of the compound formed in step 1 is reacted with 2 molar equivalents of the compound formed in step 2 to form a compound having formula (VII). The third step reaction is carried out using a suitable solvent such as acetonitrile, and the reaction mixture is stirred for 24 hours.

[0174] It should be understood that further purification and isolation steps may also be included in the process, for example between each of the above steps and after the process is completed, to purify the final compound having formula (VII).

[0175] The separation step may include a step of performing column chromatography, low pressure liquid chromatography, high performance liquid chromatography, etc. The purification step may include standard purification methods known in the art, such as filtration, evaporation, liquid-liquid extraction, crystallization, adsorption, recrystallization, chromatography, distillation, etc.

[0176] Systematic name: N1-(2-(2-isopropyl-5-methylphenoxy)-2-oxoethyl)-N10-(10-((2-(2-isopropyl-5-methylphenoxy)-2-oxoethyl)dimethylammonium)decyl)-N1,N1,N10,N10-tetramethyldecane-1,10-diammonium bromide dichloride

[0177] Molecular formula: C 50 H 88 N3O4 +3 Br - 2Cl -

[0178] Molecular weight: 946.06

[0179]

[0180] Solution 4

[0181] It will be appreciated that in order to synthesize the bromo complexes defined by formulae XI to XIV, compounds of formulae IV to VII are treated with bromine to form complexes of formulae XI to XIV. It will be appreciated that further purification and isolation steps may also be included in the process.

[0182] Example 5

[0183] Minimum inhibitory concentration (MIC) determination by broth microdilution

[0184] equipment

[0185] McFarland Standard 0.5

[0186] Falcon round bottom 5ml test tube

[0187] Disposable inoculation loops (1μl and 10μl)

[0188] Pipette tips (0.5μl-1000μl)

[0189] Tissue culture plates, 96 wells

[0190] Multi-channel micropipette (5-50μl), (30-300μl)

[0191] Disposable Petri Dish

[0192] Disposable reagent containers

[0193] Culture medium

[0194] Sterile saline

[0195] TSB (Tryptic Soy Broth)

[0196] TSA (Tryptic Soy Agar)

[0197] 0.02% Resazurin sterile solution

[0198] Bacterial strains

[0199] Staphylococcus aureus ATCC-6538

[0200] Escherichia coli ATCC-8739

[0201] program

[0202] Standardization of inoculum

[0203] From the pure o / n culture, material from at least 3-4 colonies was selected and completely suspended in 2 ml of saline in a test tube. The suspension was mixed.

[0204] The inoculum was standardized according to the 0.5 MacFarland scale (dilution factor 1:10, sterile saline solution) to obtain 1.5 x 10 4 cfu / ml. Mix the inoculum. Use the suspension for inoculation within 15 minutes.

[0205] Inoculation and incubation

[0206] Each sample was dissolved in an appropriate solvent (water / 96% ethanol) to a concentration of 5000 μg / ml. Using a serial dilution method, the concentration of the initial solution was adjusted to 625 μg / ml for Gram-negative bacteria and 78 μg / ml for Gram-positive bacteria. For fungi, the working concentration was 1250 μg / ml.

[0207] The assay was performed in 96-well plates, with each well receiving 100 μl of sterile TSB.

[0208] Add 100 μl of the sample of the initial concentration to the first well. Perform a serial dilution by transferring 100 μl from each previous well to the next well (dilution factor 1:1). In each well, add 20 μl of the inoculum. The final volume in each well is 120 μl.

[0209] The sterility of microbial growth, culture medium and solvent was controlled simultaneously. For bacteria, the plates were cultured at 37±1°C for 24 hours, and for yeast, the culture plates were cultured at 34±1°C for 48 hours. Inhibition of bacterial growth was revealed by adding a sterile solution of resazurin (20 μl, 0.02%, w / v) and re-incubating for 3 hours. The minimum inhibitory concentration (MIC) is defined as the lowest sample concentration that can inhibit microbial growth, as determined by the persistence of blue staining in the wells. A color change from blue to red (due to a reduction in the dye) indicates bacterial growth. Wells with no obvious growth were selected to evaluate the MIC, which was determined by the absence of microbial growth on a plate containing TSB.

[0210] The results of these experiments are listed in the table below.

[0211] Staphylococcus aureus ATCC 65384.5x10 3 Cfu / ml

[0212] Compound MIC / μg / mL Comparative Compound 1 1.95 Formula VII 0.98

[0213] Table 1

[0214] Escherichia coli ATCC-87396.5x103 Cfu / ml

[0215] Compound MIC / μg / mL Comparative Compound 1 7.8 Formula VII 3.9

[0216] Table 2

[0217]

[0218]

[0219] Table 3

[0220] Example 6

[0221] MIC determination by broth microdilution

[0222] equipment

[0223] McFarland Standard 0.5

[0224] Falcon round bottom 5ml test tube

[0225] Disposable inoculation loops (1μl and 10μl)

[0226] Pipette tips (0.5μl-1000μl)

[0227] Tissue culture plates, 96 wells

[0228] ·Multi-channel micropipette (5-50μl), (30-300μl) ·Disposable Petri dish

[0229] Disposable reagent containers

[0230] Culture medium

[0231] Sterile saline

[0232] TSB (Tryptic Soy Broth)

[0233] TSA (Tryptic Soy Agar)

[0234] 0.02% Resazurin sterile solution

[0235] Bacterial strains

[0236] Staphylococcus aureus ATCC-6538

[0237] Escherichia coli ATCC-8739

[0238] Pseudomonas aeruginosa ATCC-9027

[0239] Candida albicans ATCC-10231

[0240] Candida albicans NCTC-885-653

[0241] Saccharomyces cerevisiae ATCC-9763

[0242] ·Salmonella enterica serovar Typhimurium ATCC 14028

[0243] ·Saccharomyces cerevisiae ATCC-2601

[0244] program

[0245] Standardization of inoculum

[0246] From pure o / n cultures, select material from at least 3-4 colonies. Completely suspend the material in 2 ml saline in a test tube and mix.

[0247] The inoculum was standardized according to the 0.5 MacFarland scale (dilution factor 1:10, sterile saline solution) to obtain 1.5 x 10 4 cfu / ml. Mix the inoculum. Use the suspension for inoculation within 15 minutes.

[0248] Inoculation and incubation

[0249] Each sample was dissolved in an appropriate solvent (water / 96% ethanol) to a concentration of 5000 μg / ml. Using a serial dilution method, the concentration of the initial solution was adjusted to 625 μg / ml for Gram-negative bacteria and 78 μg / ml for Gram-positive bacteria. For fungi, the working concentration was 1250 μg / ml.

[0250] The assay was performed in 96-well plates, with each well receiving 100 μl of sterile TSB.

[0251] 100 μl of the sample of the initial concentration was added to the first well. Serial dilutions were performed by transferring 100 μl from each previous well to the next well (dilution factor 1:1). In each well, 20 μl of inoculum was added. The final volume in each well was 120 μl. The sterility of microbial growth, culture medium and solvents was also controlled. For bacteria, the plates were incubated at 37 ± 1 ° C for 24 hours, and for yeast, the culture plates were incubated at 34 ± 1 ° C for 48 hours. Inhibition of bacterial growth was revealed by adding a sterile solution of resazurin (20 μl, 0.02%, w / v) and re-incubating for 3 hours.

[0252] MIC is defined as the lowest sample concentration that can inhibit microbial growth, determined by the persistence of blue staining in the wells. A color change from blue to red (due to dye reduction) indicates bacterial growth. Wells with no obvious growth were selected to evaluate the MIC, which was determined by the absence of microbial growth on the plate containing TSB.

[0253] The results of these experiments are listed in the table below.

[0254] Escherichia coli ATCC-87391.7x10 4 Cfu / ml

[0255] Compound MIC / μg / mL Comparative Compound 2 7.8 Formula V 3.9 Formula IV 3.9 Vancomycin 78

[0256] Table 4

[0257] Salmonella enterica serovar Typhimurium ATCC 140281.3x10 4 Cfu / ml

[0258] Compound MIC / μg / mL Comparative Compound 2 7.8 Formula IV 3.9 Vancomycin 78

[0259] Table 5

[0260] Escherichia coli ATCC-87396.6x10 3 Cfu / ml

[0261] Compound MIC / μg / mL Comparative Compound 2 7.8 Formula V 3.9

[0262] Table 6

[0263] Pseudomonas aeruginosa ATCC-90271.9x10 4 Cfu / ml

[0264] Compound MIC / μg / mL Comparative Compound 2 7.8 Formula V 3.9

[0265] Table 7

[0266] Escherichia coli ATCC-87394.1x10 3 Cfu / ml

[0267] Compound MIC / μg / mL Comparative Compound 2 3.9 Formula V 1.95 Formula IV 1.95

[0268] Table 8

[0269] Pseudomonas aeruginosa ATCC-90274.7x10 3 Cfu / ml

[0270] Compound MIC / μg / mL Comparative Compound 2 1.95 Formula IV 0.98

[0271] Table 9

[0272]

[0273] Table 10

[0274]

[0275] Table 11

[0276] Staphylococcus aureus ATCC 65384.5x10 3 Cfu / ml

[0277] Compound MIC / μg / mL Comparative Compound 2 1.95 Formula V 0.98

[0278] Table 12

[0279] Escherichia coli ATCC-87396.5x10 3 Cfu / ml

[0280] Compound MIC / μg / mL Comparative Compound 2 7.8 Formula V 3.9 Comparative Compound 3 7.8 Formula XI 3.9

[0281] Table 13

[0282] Salmonella enterica serovar Typhimurium ATCC 14028 (log 4 conditions)

[0283] Compound MIC / mKg / mL Comparative Compound 2 7.8 Formula IV 3.9

[0284] Table 14

[0285] Escherichia coli ATCC-8739 (log 4 condition)

[0286] Compound MIC / μg / mL Comparative Compound 2 7.8 Formula V 3.9 Formula IV 3.9

[0287] Table 15

[0288] Pseudomonas aeruginosa ATCC-9027 (Log 4 condition)

[0289] Compound MIC / μg / mL Comparative Compound 3 7.8 Formula XI 3.9

[0290] Table 16

[0291] The mean MIC values ​​(μg / ml) of the different isomers were tested against various fungal strains that were either fluconazole and voriconazole resistant or susceptible clinical isolates (fungi cultured in the presence of fluconazole or voriconazole for more than 20 generations showed resistance).

[0292] The MIC values ​​of voriconazole and fluconazole for all tested strains were 255 μg / ml and 511 μg / ml, respectively.

[0293] Candida albicans ATCC-10231 voriconazole resistance (20G)

[0294] Compound MIC / μg / mL Comparative Compound 2 7.8 Formula V 3.9

[0295] Table 17

[0296] Candida albicans ATCC-10231 Fluconazole Resistance (20G)

[0297] Compound MIC / μg / mL Comparative Compound 2 15.6 Formula V 7.8

[0298] Candida albicans NTCT-885-653 voriconazole resistance (20G)

[0299] Compound MIC / μg / mL Comparative Compound 2 1.95 Formula V 0.98

[0300] Table 18

[0301] Saccharomyces cerevisiae ATCC-9763 fluconazole resistance (20G)

[0302] Compound MIC / μg / mL Comparative Compound 2 3.9 Formula IV 0.98

[0303] Table 19

[0304] Saccharomyces cerevisiae ATCC-2601 fluconazole resistance (20G)

[0305] Compound MIC / μg / mL Comparative Compound 2 1.95 Formula IV 0.98 Formula V 0.98

[0306] Table 20

[0307] Example 7

[0308] Antiviral activity

[0309] MRC5 cells were seeded in 96-well plates at a density of 20,000 cells / well and cultured overnight at 37°C, 5% CO2. The next day, medium containing serially diluted compounds and viruses was added to the wells. The resulting cultures were incubated at 37°C, 5% CO2. Four days after infection, the medium was replenished. Seven days after infection, fluorescence intensity was determined using Acumen Cellista. The antiviral activity of the compounds was calculated based on the inhibition of GFP expression at each concentration normalized by cell controls. The cytotoxicity of the compounds was evaluated in parallel under the same conditions but without viral infection. Cell viability was measured using CCK8 according to the manufacturer's manual.

[0310] The antiviral activity and cytotoxicity of the compounds were expressed as % inhibition and % viability, respectively, and calculated using the following formula:

[0311] Inhibition (%) = 100-(original data CPD-average CC) / (average VC-average CC)*100 Viability (%) = (original data CPD-average MC) / (average CC-average MC)*100

[0312] The raw data CPD represents the value of the compound-treated wells; the average VC, average CC and average MC represent the average values ​​of the virus control wells, cell control wells and medium control wells, respectively.

[0313] EC50 and CC50 values ​​were calculated using GraphPad Prism software.

[0314]

[0315] Table 21

[0316] The experimental results are listed in Table 22 below.

[0317]

[0318] Table 22

[0319]

[0320]

[0321] Table 23.

Claims

1. A compound having the formula: in, R is an alkylene chain having 8 to 20 carbon atoms, A is one or more halide anions having a total charge of -2; Alternatively, R is a quaternary amine having the formula: Where R a and R b Each is an alkylene chain having 8 to 20 carbon atoms, A is one or more halide anions with a total charge of -3; R1, R2, R3, R4, R5 and R6 are each independently selected from C 1-4 alkyl; E has the following formula wherein the ester oxygen is bonded to the aromatic ring of each E at the same position, which is the 2-position or the 3-position; and wherein R E is H or halogen.

2. The compound according to claim 1, which has the following formula:

3. The compound according to claim 1, wherein R is a saturated linear alkylene chain having 8 to 16 carbon atoms. The compound according to claim 3 , wherein R is a saturated linear alkylene chain having 10 carbon atoms.

5. The compound according to claim 1, wherein R a and R b Each is a saturated straight alkylene chain having 8 to 16 carbon atoms.

6. The compound according to claim 5, wherein R a and R b Each is a saturated straight alkylene chain having 10 carbon atoms.

7. The compound according to any one of claims 1 to 6, wherein the one or more halide anions are selected from chloride anions and bromide anions.

8. A compound according to any one of claims 1 to 6, wherein R1, R2, R3, R4, R5 and R6 are each methyl.

9. The compound according to claim 1, which has the following formula:

10. A compound having the formula: wherein R is an alkylene chain having 8 to 20 carbon atoms, A is one or more halide anions with a total charge of -2, Alternatively, R is a quaternary amine having the formula: Where R a and R bEach is an alkylene chain having 8 to 20 carbon atoms, A is one or more halide anions with a total charge of -3; R1, R2, R3, R4, R5 and R6 are each independently selected from C 1-4 alkyl; E has the following formula wherein the ester oxygen is bonded to the aromatic ring of each E at the same position, which is the 2-position or the 3-position; wherein R E is H or halogen, and wherein X is 2, 3, 4 or 6.

11. The compound according to claim 10, which has the following formula:

12. The compound according to claim 10, wherein R is a saturated linear alkylene chain having 8 to 16 carbon atoms.

13. The compound according to claim 12, wherein R is a saturated linear alkylene chain having 10 carbon atoms.

14. The compound according to claim 10, wherein R a and R b Each is a saturated straight alkylene chain having 8 to 16 carbon atoms.

15. The compound according to claim 14, wherein R a and R b Each is a saturated straight alkylene chain having 10 carbon atoms.

16. The compound according to any one of claims 10 to 15, wherein the one or more halide anions are selected from chloride anions and bromide anions.

17. The compound according to claim 10 or 11, which has the following formula: Where X is 3 or 6.

18. A pharmaceutical composition comprising the compound of any one of claims 1 to 17.

19. Use of a compound according to any one of claims 1 to 17 in the preparation of a medicament for the treatment of fungal and / or bacterial infections.

20. Use of a compound according to any one of claims 1 to 17 in the preparation of a medicament for the treatment of herpes virus and / or human papillomavirus.

21. A method for producing the compound of claim 1, comprising: i) making a compound having formula (XV) The alcohol group is bonded to the benzene ring at the 2- or 3-position, R E is H or halogen, reacts with R7CH2COCl to form a compound having formula (XVI): Where R7 is chlorine or bromine, E is wherein the ester oxygen is bonded to the aromatic ring of E at the 2-position or 3-position, and wherein R E is H or a halogen; and ii) one molar equivalent of a compound having formula (XVII) and reacted with 2 moles of a compound having formula (XVI) to form a compound having the following formula: wherein R is an alkylene chain having 8 to 20 carbon atoms, and A is one or more halide anions having a total charge of -2; Alternatively, R is a quaternary amine having the formula: Where R a and R b Each is an alkylene chain having 8 to 20 carbon atoms, A is one or more halide anions with a total charge of -3; E has the following formula wherein the ester oxygen is bonded to the aromatic ring of each E at the same position, which is the 2-position or the 3-position; and wherein R E is H or halogen; R1, R2, R3, R4, R5 and R6 are each independently selected from C 1-4 alkyl.

22. The method according to claim 21, wherein the reaction in step II is carried out in acetonitrile as a solvent.

23. A method for producing the compound of claim 10, comprising subjecting a compound having formula (I) to Reaction with bromine to form a compound having formula (VIII) wherein R is an alkylene chain having 8 to 20 carbon atoms, A is one or more halide anions with a total charge of -2, Alternatively, R is a quaternary amine having the formula: Where R a and R b Each is an alkylene chain having 8 to 20 carbon atoms, A is one or more halide anions with a total charge of -3; R1, R2, R3, R4, R5 and R6 are each independently selected from C 1-4 alkyl; E has the following formula wherein the ester oxygen is bonded to the aromatic ring of each E at the same position, which is the 2-position or the 3-position; wherein R E is H or halogen; and wherein X is 2, 3, 4 or 6.

Citation Information

Patent Citations

  • Compounds and compositions

    WO2018132066A1

  • Compounds and compositions

    CN110382053A